scholarly journals Pain Relief and Safety Outcomes with Cervical 10 kHz Spinal Cord Stimulation: Systematic Literature Review and Meta-analysis

2021 ◽  
Author(s):  
Ganesan Baranidharan ◽  
Beatrice Bretherton ◽  
Craig Montgomery ◽  
John Titterington ◽  
Tracey Crowther ◽  
...  
Neurosurgery ◽  
1991 ◽  
Vol 28 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Roberto Spiegelmann ◽  
William A. Friedman

Abstract Forty-three patients with chronic pain disorders of different causes were selected for spinal cord stimulation. All underwent implantation of a ribbon electrode through a small laminotomy, under general anesthesia. Thirteen patients (30%) failed to obtain significant pain relief during a period of trial stimulation, and their electrodes were removed. The remainder underwent a definitive implant and were followed for a mean of 13 months (range, 3-33 months). Nineteen of them (63%) continued to experience pain relief. A detailed analysis of this series, as well as a literature review, is presented.


Pain ◽  
2010 ◽  
Vol 150 (2) ◽  
pp. 284-289 ◽  
Author(s):  
Elizabeth Sparkes ◽  
Jon H. Raphael ◽  
Rui V. Duarte ◽  
Karen LeMarchand ◽  
Craig Jackson ◽  
...  

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Céline El Baou ◽  
Rachael L. DiSantostefano ◽  
Rafael Alfonso-Cristancho ◽  
Elizabeth A. Suarez ◽  
David Stempel ◽  
...  

2017 ◽  
Vol 76 (6) ◽  
pp. 1101-1136 ◽  
Author(s):  
Sofia Ramiro ◽  
Alexandre Sepriano ◽  
Katerina Chatzidionysiou ◽  
Jackie L Nam ◽  
Josef S Smolen ◽  
...  

ObjectivesTo assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA.MethodsSystematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included. Risk of bias was assessed with the Hayden's tool.ResultsTwenty-six observational studies addressing diverse safety outcomes of therapy with bDMARDs met eligibility criteria (15 on serious infections, 4 on malignancies). Substantial heterogeneity precluded meta-analysis. Together with the evidence from the 2013 SLR, based on 15 studies, 7 at low risk of bias, patients on bDMARDs compared with patients on conventional sDMARDs had a higher risk of serious infections (adjusted HR (aHR) 1.1 to 1.8)—without differences across bDMARDs—a higher risk of tuberculosis (aHR 2.7 to 12.5), but no increased risk of infection by herpes zoster. Patients on bDMARDs did not have an increased risk of malignancies in general, lymphoma or non-melanoma skin cancer, but the risk of melanoma may be slightly increased (aHR 1.5).ConclusionsThese findings confirm the known safety pattern of bDMARDs, including both tumour necrosis factor-α inhibitor (TNFi) and non-TNFi, for the treatment of RA.


2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Céline El Baou ◽  
Rachael L. Di Santostefano ◽  
Rafael Alfonso-Cristancho ◽  
Elizabeth A Suarez ◽  
David Stempel ◽  
...  

2019 ◽  
Vol 123 ◽  
pp. 58-71 ◽  
Author(s):  
Margreet G. Franken ◽  
Brenda Leeneman ◽  
Maria Gheorghe ◽  
Carin A. Uyl-de Groot ◽  
John B.A.G. Haanen ◽  
...  

Author(s):  
Jan M. Eckermann ◽  
Julie G. Pilitsis ◽  
Christopher Vannaboutathong ◽  
Belinda J. Wagner ◽  
Rose Province‐Azalde ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document